cnb791 ht logo promo |

Introducing the new PhysioMimix Single-Organ Higher Throughput System

Learn more
CN Bio logo CN Bio logo CN Bio logo CN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • SLAS Europe 2023

      • SOT 2023

      • WORD 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      • Doctoral Researcher (Horizon Marie Curie Doctoral Network Project)

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

March 14, 2023 by CN Bio

Cambridge, UK, 14 March 2023: CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing. Deepak’s appointment supports the Company’s next phase of commercial development as it expands international operations, product research and development and sales in key global markets.

deepak-vp-sales-marketing

Bringing over 30 years of commercial experience within life sciences, Deepak’s appointment follows that of Dr Paul Brooks as CEO in December 20221, to drive CN Bio’s international scale-up operations for both the product and service sides of the business. This includes supporting the recent launch of the Company’s PhysioMimix® Single-organ Higher-Throughput (HT) System2, designed to overcome adoption barriers currently limiting the use of predictive human liver models within drug discovery workflows, enabling use within earlier stages where larger-scale comparative studies that investigate the efficacy, disposition or safety of lead candidate drugs are required.

Throughout his extensive career in the commercial life sciences sector, Deepak has provided leadership for high-performance sales and marketing teams to establish new technologies, from commercialisation through to global scale-up, as well as supporting expansion of existing products and services into the drug discovery, bioproduction, research and diagnostics markets. He joins CN Bio from PerkinElmer’s Horizon Discovery where he was Head of Global Commercial. Prior to this, Deepak was with Pacific Biosciences as Vice President of EMEA Operations.  He also held senior-level sales and marketing positions at Affymetrix and the Genetic Analysis Unit of Applied Biosystems (formerly a PerkinElmer company). Deepak has a BSc in Biotechnology from the Polytechnic of Central London.


Deepak Singh, VP Sales and Marketing at CN Bio, commented: “Having had extensive experience within the life science industry, I am excited by the possibilities of OOC technology, and how fast the potential of this technology is being realised. As evidenced by the recent FDA Modernization Act 2.0 legislation in the US, this is a very promising time for the technology, and I am looking forward to joining the CN Bio team to bring their cutting-edge systems to more researchers across the globe, to enable decision-making within drug discovery workflows to be made with more confidence and earlier than ever before.”


Dr Paul Brooks, CEO at CN Bio, said: “Deepak’s business and leadership experience, alongside his life science background, is of huge value to CN Bio as we drive forward with  the Company’s commercial excellence strategy and build our capabilities in 2023 and beyond. Following the successful launch of our PhysioMimix Single-organ HT System in February, Deepak joins us at an exciting time and will be pivotal for the international scale-up of the marketing and distribution of this new system and our existing portfolio of MPS products and services.”


  1. Press release (19th December, 2022): CN Bio appoints Dr Paul Brooks as Chief Executive Officer https://cn-bio.com/cn-bio-appoints-dr-paul-brooks-as-chief-executive-officer/
  2. Press release (27th February, 2023): CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System https://cn-bio.com/cn-bio-extends-microphysiological-system-portfolio-with-physiomimix-single-organ-higher-throughput-system/

Category iconPress releases

Primary Sidebar

Other recent news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023
  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SOT 2023 March 19-23, 2023

WORD 2023 March 22, 2022